

## Enantioselective Synthesis of the Taxol and Taxotere Side Chains

Ari M. P. Koskinen,\* Esko K. Karvinen and Jussi P. Siirilä

Department of Chemistry, University of Oulu, Linnanmaa SF-90570 Oulu, Finland


A new route to Taxol and Taxotere side chains via asymmetric dihydroxylation of both *cis* and *trans* methyl cinnamates is described.

Taxol<sup>1-3</sup> is a diterpene with anticancer activity isolated in low yields from the bark of the Pacific yew tree (*Taxus brevifolia*). Its total synthesis remains elusive. Thus, semisynthesis via 10-deacetyl baccatin III and a properly protected 3-phenyl isoserine is possible.<sup>4</sup> The semisynthetic Taxol derivative Taxotere,<sup>5</sup> is also accessible from 10-deacetyl baccatin III and *N-tert* butoxycarbonyl-3-phenyl isoserine.<sup>6</sup> A number of methods for the synthesis of the side chain derivatives have been published.<sup>6,7</sup> In this communication, we report the enantioselective synthesis of Taxol and Taxotere side chains starting from both *cis*- and *trans*-methyl cinnamate, (Scheme 1).<sup>†</sup>


Asymmetric dihydroxylation with AD-mix- $\beta^8$  of *cis*-methyl cinnamate gave the diol **2** in 36% yield (7% optical purity). The diol was then allowed to react with thionyl chloride in CCl<sub>4</sub> to give a diastereoisomeric mixture of cyclic sulfites, which were oxidised immediately to the corresponding sulfate **3** using a catalytic amount of RuCl<sub>3</sub> with sodium periodate as the stoichiometric oxidant.<sup>9</sup> Treatment of the sulfate **3** with sodium azide in acetone-water<sup>9a</sup> for 2-3 h at room temp. gave the desired azido alcohol **4** after hydrolysis in 81% yield. Based on <sup>1</sup>H NMR, only traces (<5%) of the regioisomeric alcohol could have been present in the crude product. Catalytic reduction (10% Pd/C) of **4** in the presence of two equivalents of di-*tert*-butyl dicarbonate in methanol gave the Taxotere side chain methyl ester **5** in 78% yield after flash chromatography. Benzoylation of the azido alcohol **4** with benzoyl chloride in dichloromethane in the presence of DMAP<sup>7d</sup> gave the benzoate **6** in 77% yield. Reduction of the azide in methanol with concomitant acyl migration<sup>7a</sup> from oxygen to nitrogen gave the Taxol side chain methyl ester **7** in good yield. Asymmetric dihydroxylation of *Z*-alkenes is known to proceed with only modest enantioselectivity,<sup>8,10</sup> and thus the enantiopurity achieved with this sequence was unacceptably low. This fact together with the known difficulties in the preparation of *cis*-cinnamic esters<sup>11</sup> prompted us to search for an alternative route.

The commercially available and inexpensive *trans*-methyl cinnamate **8** was subjected to asymmetric dihydroxylation as

above with AD-mix- $\alpha$  and the diol **9**<sup>12‡</sup> thus obtained was transformed to the corresponding sulfate **10** as described above (Scheme 2). The sulfate **10** was treated with ammonium bromide in acetone overnight at room temp. to give a *ca* 9:1 mixture of regioisomeric hydroxy bromides with the desired **11** predominating. The mixture of bromides was treated with sodium azide in dimethylformamide (DMF) at 65-75 °C to furnish the azido alcohol **4** in 80% yield as a 4:1 mixture of diastereoisomers after flash chromatography.<sup>7d</sup> This mixture could be purified on normal phase HPLC to give pure **4**.<sup>§</sup> It was more convenient to transform this diastereoisomer mixture to the Taxol and Taxotere side chains as described above, and separate the diastereoisomers at the final stage by crystallization.<sup>¶</sup> In this context it is worth mentioning that the (2*S*, 3*S*) azido alcohol has recently been transformed to the Taxol side chain by Gou *et al.*<sup>7d</sup> This diastereoisomeric azide is accessible by our method in three steps through AD of



**Scheme 1** Synthesis of the Taxol and Taxotere side chains from *Z*-cinnamate; *Reagents and conditions*: i, AD-mix- $\beta^8$  (36%); ii, SOCl<sub>2</sub>, CCl<sub>4</sub>; iii, RuCl<sub>3</sub>, NaIO<sub>4</sub>, MeCN, CCl<sub>4</sub> (60%); iv, NaN<sub>3</sub>, Me<sub>2</sub>CO, H<sub>2</sub>O (81%); v, H<sub>2</sub>, Pd/C, (Boc)<sub>2</sub>O, MeOH (78%); vi, PhCOCl, DMAP, CH<sub>2</sub>Cl<sub>2</sub> (77%); vii, H<sub>2</sub>, Pd/C, MeOH (77%)



**Scheme 2** Synthesis of the Taxol and Taxotere side chains from *E*-cinnamate; *Reagents and conditions*: i, AD-mix- $\alpha^8$  (72%); ii,  $\text{SOCl}_2$ ,  $\text{CCl}_4$ ; iii,  $\text{RuCl}_3$ ,  $\text{NaIO}_4$ ,  $\text{MeCN}$ ,  $\text{CCl}_4$  (61%); iv,  $\text{NH}_4\text{Br}$ ,  $\text{Me}_2\text{Co}$  (86%); v,  $\text{NaN}_3$ ,  $\text{DMF}$  (80%); For **9**,  $[\alpha]_D + 12.2$  (0.213,  $\text{CHCl}_3$ )

*trans*-methyl cinnamate with AD-mix- $\beta$  followed by sulfate formation and opening of the sulfate with sodium azide as described above.

This work was made possible by a grant from the Technology Development Centre (TEKES, Finland). We thank Professor K. Barry Sharpless for helpful discussions.

Received, 13th August 1993; Com. 3/04916G

### Footnotes

† All compounds exhibited satisfactory analytical and spectral data.

‡ The enantiopurity of compound **9** was determined to be 92% ee by chiral phase GLC ( $\beta$ -cyclodextrin column, isothermal,  $150^\circ\text{C}$ ).

§  $[\alpha]_D + 144.7$  (c 0.44,  $\text{CHCl}_3$ ), lit.<sup>7c</sup>  $[\alpha]_D + 142$  (c 1.1,  $\text{CHCl}_3$ ). This material was determined to be > 97% ee (DAICEL-OD, 5%  $\text{Pr}^i\text{OH}$  in hexanes).

¶ Crystallised Taxotere side chain **5** gave  $[\alpha]_D - 7.3$  (c 0.60,  $\text{CHCl}_3$ ). lit.<sup>7c</sup>  $[\alpha]_D - 7$  (c 1.2,  $\text{CHCl}_3$ ). Crystallised Taxol side chain **7** gave  $[\alpha]_D - 46.8$  (c 1.0,  $\text{MeOH}$ ), lit.<sup>7c</sup>  $[\alpha]_D - 48$  (c 1.0,  $\text{MeOH}$ ).

### References

- M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon and A. T. McPhall, *J. Am. Chem. Soc.*, 1971, **93**, 2325.
- FDA has very recently approved Taxol for the treatment of patients with ovarian cancer, whose first-line or subsequent chemotherapy has failed, see: *Pharmaceutical Business News*, 1993, January 8, 7; *Chem. Ind.*, 1993, 41.
- S. Borman, *Chem. Eng. News*, 1991, September 2, 11; for recent reviews see: C. S. Swindell, *Org. Prep. Proced. Int.*, 1991, **23**, 465; D. G. I. Kingston, *Pharmac. Ther.*, 1991, **52**, 1; D. G. I. Kingston, G. Samaranyake and C. A. Ivey, *J. Nat. Prod.*, 1990, **53**, 1; W. J. Slichenmyer and D. D. Von Hoff, *Anti-Cancer Drugs*, 1991, **2**, 519; S. Blechert and D. Guenard, *The Alkaloids*, 1990, **39**, 195.
- J.-N. Denis, A. E. Greene, D. Guénard, F. Guéritte-Voegelain, L. Mangatana and P. Potier, *J. Am. Chem. Soc.*, 1988, **110**, 5917.
- F. Guéritte-Voegelain, D. Guénard, F. Lavelle, M.-T. Le Goff, L. Mangatana and P. Potier, *J. Med. Chem.*, 1991, **34**, 992.
- A. Commercon, D. Bézard, F. Bernard and J. D. Bourzat, *Tetrahedron Lett.*, 1992, **33**, 5185.
- (a) J.-N. Denis, A. E. Greene, A. A. Serra, and M.-J. Luche, *J. Org. Chem.*, 1986, **51**, 46; (b) H. Hönl, P. Seuffer-Wasserthal and H. Weber, *Tetrahedron*, 1990, **46**, 3841; (c) J.-N. Denis, A. Correa and A. E. Greene, *J. Org. Chem.*, 1990, **55**, 1957; (d) D.-M. Gou, Y.-C. Liu and C.-S. Chen, *J. Org. Chem.*, 1993, **58**, 1287; (e) L. Deng and E. N. Jacobsen, *J. Org. Chem.*, 1992, **57**, 4320; (f) M. E. Bunnage, S. G. Davies and C. J. Goodwin, *J. Chem. Soc., Perkin Trans. I*, 1993, 1375 and references therein.
- K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K.-S. Jeong, H.-L. Kwong, K. Morikawa, Z.-M. Wang, D. Xu and X.-L. Zhang, *J. Org. Chem.*, 1992, **57**, 2768 and references therein; for a review see B. B. Lohray, *Tetrahedron: Asymmetry*, 1992, **3**, 1317.
- (a) Y. Gao and K. B. Sharpless, *J. Org. Chem.*, 1988, **110**, 7538; (b) B. M. Kim and K. B. Sharpless, *Tetrahedron Lett.*, 1989, **30**, 655; (c) M. S. Berrige, M. P. Franceschini, E. Rosenfeld and T. J. Tewson, *J. Org. Chem.*, 1990, **55**, 1211; (d) for a review on cyclic sulfites and cyclic sulfates see: B. B. Lohray, *Synthesis*, 1992, 1035.
- New ligands which are not available commercially allow ees reaching 80%, cf. L. Wang and K. B. Sharpless, *J. Am. Chem. Soc.*, 1992, **114**, 7568; K. Fujii, K. Tanaka and H. Miyamoto, *Tetrahedron Lett.*, 1992, **28**, 4021.
- The reduction of phenyl propiolates always gives a product mixture containing in addition to the *Z*-ester also *E*-ester and over-reduced alkane see e.g. ref. 7e.
- For the enantiomer of **9**,  $[\alpha]_D - 12.7$  (c 0.30,  $\text{CHCl}_3$ ) has been reported: B. R. Matthews, W. R. Jackson, H. A. Jacobs and K. G. Watson, *Aust. J. Chem.*, 1990, **43**, 1195. However, this reference does not provide conclusive proof of the optical purity of the compound.